A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 1109 (Primary)
- Indications Anthrax
- Focus Pharmacodynamics
- Sponsors GC Pharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 24 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 24 Feb 2016 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.